DR. CHRISTINA ERNST
Christina obtained her BSc in Molecular Cell Biology from the University of Heidelberg in Germany, followed by a MSc in Molecular Biosciences with a major in Cancer Biology in collaboration with the German Cancer Research Center (DKFZ).
She then joined Duncan Odom‘s laboratory at Cancer Research UK – Cambridge Institute (CRUK-CI) and obtained her PhD from the University of Cambridge in 2018. Afterwards, she did a short bridging-postdoc with John Marioni at the European Bioinformatics Institute (EMBL-EBI), before joining Didier Trono’s laboratory at EPFL as a Human Frontiers Long-Term Fellow (HFSP-LTF).
Visiting PhD Student
Fabian studied biology at the RWTH Aachen University, where he specialised in cellular and molecular biology, and is currently pursuing his PhD at the Max-Planck Institute for Molecular Biomedicine in Münster.
He is visiting our laboratory to explore RNA-protein interactions during early embryogenesis and received a Travelling Fellowship from the Company of Biologists to facilitate his visit.
Daniel Margarido Galán
Daniel studied Biochemistry at the Autonomous University of Madrid and obtained his MSc in Molecular Medicine at the Norwegian University of Science and Technology (NTNU).
He is currently carrying out a 6-month internship in our laboratory contributing to the adaptation and optimisation of our custom library preparation strategy for its application to various RNA-sequencing protocols. His project is supported by an enable grant from the EPFL Technology Transfer Office (TTO).
Get in touch!
We are always interested to hear from enthusiastic candidates that would like to join our team!
In particular, we are looking for highly motivated students that would like to carry out an internship or Master thesis project in our lab.
Please get in touch to discuss available projects and send a copy of your CV as well as your research interests to Christina Ernst.
For more opportunities, please contact Christina Ernst directly to discuss different options, as well as possibilities for third-party funding.